sulfasalazine has been researched along with Leukocytopenia in 21 studies
Sulfasalazine: A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907)
sulfasalazine : An azobenzene consisting of diphenyldiazene having a carboxy substituent at the 4-position, a hydroxy substituent at the 3-position and a 2-pyridylaminosulphonyl substituent at the 4'-position.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Despite NUDT15 variants showing significant association with thiopurine-induced adverse events (AEs) in Asians, it remains unclear which variants of NUDT15 or whether additional genetic variants should be tested to predict AEs." | 1.48 | NUDT15 codon 139 is the best pharmacogenetic marker for predicting thiopurine-induced severe adverse events in Japanese patients with inflammatory bowel disease: a multicenter study. ( Andoh, A; Araki, H; Endo, K; Hanai, H; Hiraoka, S; Hisamatsu, T; Hokari, R; Ikeya, K; Ishiguro, Y; Kakuta, Y; Kawai, Y; Kinouchi, Y; Kobayashi, T; Masamune, A; Matsumoto, T; Miura, M; Mizuno, S; Moroi, R; Motoya, S; Naganuma, M; Nagasaki, M; Naito, T; Nakagawa, S; Nakagawa, T; Nakamura, S; Nakase, H; Nishida, A; Okamoto, D; Onodera, K; Sakuraba, H; Sasaki, M; Shiga, H; Shimosegawa, T; Shinozaki, M; Suzuki, Y; Takagawa, T; Takahara, M; Toyonaga, T; Yanai, S, 2018) |
| "A 29-year-old male patient with ulcerative colitis, who underwent haemodialysis thrice a week because of severe renal dysfunction." | 1.32 | Sulphasalazine-induced leucopenia in a patient with renal dysfunction. ( Hino, B; Iida, M; Itoh, Y; Joh, Y; Makino, K; Oishi, R; Teshima, D; Yano, T, 2003) |
| "In patients with Crohn's disease on long term azathioprine therapy, it is clear that myelosuppression, particularly leucopenia, is caused by other factors in addition to variable TPMT activity and therefore monitoring of blood cell counts throughout treatment is essential." | 1.31 | TPMT in the treatment of Crohn's disease with azathioprine. ( Lennard, L, 2002) |
| " The incidence and nature of adverse effects occurring in 774 patients with rheumatoid arthritis treated with sulphasalazine for periods ranging from one to 11 years were therefore noted." | 1.27 | Sulphasalazine for rheumatoid arthritis: toxicity in 774 patients monitored for one to 11 years. ( Amos, RS; Bax, DE; Capell, HA; McConkey, B; Pullar, T; Situnayake, D, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 13 (61.90) | 18.7374 |
| 1990's | 3 (14.29) | 18.2507 |
| 2000's | 3 (14.29) | 29.6817 |
| 2010's | 2 (9.52) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kakuta, Y | 1 |
| Kawai, Y | 1 |
| Okamoto, D | 1 |
| Takagawa, T | 1 |
| Ikeya, K | 1 |
| Sakuraba, H | 1 |
| Nishida, A | 1 |
| Nakagawa, S | 1 |
| Miura, M | 1 |
| Toyonaga, T | 1 |
| Onodera, K | 1 |
| Shinozaki, M | 1 |
| Ishiguro, Y | 1 |
| Mizuno, S | 1 |
| Takahara, M | 1 |
| Yanai, S | 1 |
| Hokari, R | 1 |
| Nakagawa, T | 1 |
| Araki, H | 1 |
| Motoya, S | 1 |
| Naito, T | 1 |
| Moroi, R | 1 |
| Shiga, H | 1 |
| Endo, K | 1 |
| Kobayashi, T | 1 |
| Naganuma, M | 1 |
| Hiraoka, S | 1 |
| Matsumoto, T | 1 |
| Nakamura, S | 1 |
| Nakase, H | 1 |
| Hisamatsu, T | 1 |
| Sasaki, M | 1 |
| Hanai, H | 1 |
| Andoh, A | 1 |
| Nagasaki, M | 1 |
| Kinouchi, Y | 1 |
| Shimosegawa, T | 1 |
| Masamune, A | 1 |
| Suzuki, Y | 1 |
| Masuda, H | 1 |
| Takahashi, Y | 1 |
| Nishida, Y | 1 |
| Asai, S | 1 |
| Lennard, L | 1 |
| Teshima, D | 1 |
| Hino, B | 1 |
| Makino, K | 1 |
| Yano, T | 1 |
| Itoh, Y | 1 |
| Joh, Y | 1 |
| Iida, M | 1 |
| Oishi, R | 1 |
| McKenna, KE | 1 |
| Burrows, D | 1 |
| Lowry, PW | 1 |
| Franklin, CL | 1 |
| Weaver, AL | 1 |
| Szumlanski, CL | 1 |
| Mays, DC | 1 |
| Loftus, EV | 1 |
| Tremaine, WJ | 1 |
| Lipsky, JJ | 1 |
| Weinshilboum, RM | 1 |
| Sandborn, WJ | 1 |
| Porter, D | 1 |
| Madhok, R | 2 |
| Hunter, JA | 3 |
| Capell, HA | 4 |
| Schmidt, KL | 1 |
| Marabani, M | 1 |
| Ridley, MG | 1 |
| Cheung, NT | 1 |
| Myles, AB | 1 |
| Bliddal, H | 3 |
| Eiberg, B | 2 |
| Helin, P | 3 |
| Svejgaard, A | 1 |
| Bax, DE | 3 |
| Amos, RS | 3 |
| Situnayake, D | 2 |
| McConkey, B | 2 |
| Pullar, T | 2 |
| Farr, M | 1 |
| Symmons, DP | 1 |
| Blake, DR | 1 |
| Bacon, PA | 1 |
| Korelitz, BI | 2 |
| Glass, JL | 1 |
| Wisch, N | 2 |
| Das, KM | 1 |
| Eastwood, MA | 1 |
| McManus, JP | 1 |
| Sircus, W | 1 |
1 trial available for sulfasalazine and Leukocytopenia
| Article | Year |
|---|---|
Prospective trial comparing the use of sulphasalazine and auranofin as second line drugs in patients with rheumatoid arthritis.
Topics: Adult; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Auranofin; Blood Sedimentation; C-Reactive Pr | 1992 |
20 other studies available for sulfasalazine and Leukocytopenia
| Article | Year |
|---|---|
NUDT15 codon 139 is the best pharmacogenetic marker for predicting thiopurine-induced severe adverse events in Japanese patients with inflammatory bowel disease: a multicenter study.
Topics: Alopecia; Antibodies, Monoclonal; Azathioprine; Biomarkers, Pharmacological; Genetic Predisposition | 2018 |
Comparison of the effect of mesalazine and sulfasalazine on laboratory parameters: a retrospective observational study.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Chemical and Drug Induced Liver Injury; Cohort Studi | 2012 |
TPMT in the treatment of Crohn's disease with azathioprine.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Biomarkers; Crohn Disease; Drug Interactions; | 2002 |
Sulphasalazine-induced leucopenia in a patient with renal dysfunction.
Topics: Adult; Arylamine N-Acetyltransferase; Colitis, Ulcerative; Gastrointestinal Agents; Humans; Kidney D | 2003 |
Leucopenia, thrombocytopenia and lymphadenopathy associated with sulphasalazine.
Topics: Adult; Female; Humans; Leukopenia; Lymphatic Diseases; Psoriasis; Sulfasalazine; Thrombocytopenia | 1994 |
Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide.
Topics: Adult; Aminosalicylic Acids; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Azathiop | 2001 |
Leucopenia after gold and sulphasalazine treatment.
Topics: Gold Sodium Thiomalate; HLA-B27 Antigen; Humans; Leukopenia; Risk Factors; Sulfasalazine | 1990 |
Leucopenia during sulphasalazine treatment for rheumatoid arthritis.
Topics: Adult; Aged; Arthritis, Rheumatoid; Cohort Studies; Female; Humans; Leukopenia; Male; Middle Aged; P | 1989 |
Profound leucopenia with Salazopyrin EN.
Topics: Aged; Arthritis, Rheumatoid; Humans; Leukopenia; Male; Sulfasalazine | 1989 |
HLA types in patients with rheumatoid arthritis developing leucopenia after both gold and sulphasalazine treatment.
Topics: Adult; Arthritis, Rheumatoid; Female; Gold Sodium Thiomalate; HLA-DR Antigens; Humans; Leukopenia; M | 1989 |
Sulphasalazine in rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Humans; Leukopenia; Sulfasalazine | 1985 |
Sulphasalazine for rheumatoid arthritis: toxicity in 774 patients monitored for one to 11 years.
Topics: Adolescent; Adult; Aged; Arthritis, Rheumatoid; Female; Humans; Leukopenia; Male; Middle Aged; Sulfa | 1986 |
Neutropenia in patients with inflammatory arthritis treated with sulphasalazine.
Topics: Acute Disease; Adult; Agranulocytosis; Arthritis; Humans; Leukopenia; Male; Middle Aged; Neutropenia | 1986 |
Comparison of white blood cell dyscrasias during sulphasalazine therapy of rheumatoid arthritis and inflammatory bowel disease.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Colitis, Ulcerative; Crohn Dis | 1986 |
Gold-induced leucopenia may predict a similar adverse reaction to sulphasalazine.
Topics: Adult; Female; Gold; Humans; Leukopenia; Middle Aged; Probability; Sulfasalazine | 1987 |
Leucopenia in adult Still's disease during treatment with azathioprine and sulphasalazine.
Topics: Adult; Arthritis, Juvenile; Aspirin; Azathioprine; Drug Therapy, Combination; Humans; Leukopenia; Ma | 1987 |
Leucopenia in rheumatoid arthritis: relationship to gold or sulphasalazine therapy.
Topics: Adult; Aged; Arthritis, Rheumatoid; Blood Sedimentation; Female; Gold; Humans; Leukocyte Count; Leuk | 1988 |
Long-term immunosuppressive therapy of ulcerative colitis. Continuation of a personal series.
Topics: Adolescent; Adrenocorticotropic Hormone; Adult; Child; Child, Preschool; Colitis, Ulcerative; Female | 1973 |
Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype.
Topics: Acetylation; Agranulocytosis; Aminosalicylic Acids; Anemia, Hemolytic; Colitis, Ulcerative; Crohn Di | 1973 |
Long term therapy of ulcerative colitis with 6-mercaptopurine: a personal series.
Topics: Adolescent; Adrenocorticotropic Hormone; Adult; Aged; Child; Child, Preschool; Colitis, Ulcerative; | 1972 |